Formulary Watch
Latest News
All News
Advertisement
FDA cleared the first medical device to treat attention deficit hyperactivity disorder (ADHD) in kids.
A Commonwealth Fund study has revealing findings about PBMs’ use of rebates and impact on drug prices.
Metastatic breast cancer drug expands treatment to men.
FDA cleared Dovato (ViiV Healthcare), the first 2-drug regimen to treat HIV-1 in adults with no antiretroviral treatment history.
FDA fast-tracks biosimiliar insulin products to elevate competition.
FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.
Postpartum drug is a game changer, but can women afford it?
Several companies are recalling products due to contamination from substances such as carcinogens and glass-here’s what you should know.
Nasal spray offers promise for treatment-resistant depression, but proceed with caution.
How FDA Chief Gottlieb’s resignation could impact the pharma industry.
The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.
FDA is warning about an increased risk of death and blood clots in the lungs in patients with rheumatoid arthritis taking a specific dosage of this drug.
Many patients who were prescribed fentanyl should not have received the drug, a new study said.
FDA is requiring the addition of a Black Box Warning to a gout drug that has an increased risk of death.
FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.
In his recent State of the Union address, President Trump promised to continue lowering drug prices and fund research for HIV/AIDS and childhood cancer. Here are the ways experts say he will implement those pledges.
FDA warns companies illegally selling drugs and dietary supplements claiming to cure Alzheimer’s and other conditions.
FDA approved the first generic of a popular inhaler to treat asthma and chronic obstructive pulmonary disease
CVS Health adds new migraine drugs to its list of covered drugs, but excludes one rival treatment.
FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
What employees may miss when they buy drugs directly online
5